Kala Pharmaceuticals, Inc.
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
18.2%
2 terminated/withdrawn out of 11 trials
81.8%
-4.7% vs industry average
64%
7 trials in Phase 3/4
111%
10 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
Role: collaborator
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Role: collaborator
Safety and Efficacy of KPI-121 in Subjects With DED
Role: lead
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Role: lead
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
Role: lead
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
Role: lead
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Role: lead
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Role: lead
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
Role: lead
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
Role: lead
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Role: lead
All 11 trials loaded